Cocrystal Pharma Q3 EPS $(0.41) Beats $(0.53) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cocrystal Pharma (NASDAQ:COCP) reported a smaller-than-expected loss of $(0.41) per share for Q3, beating the consensus estimate of $(0.53) by 22.64%. This represents a 41.43% improvement from the $(0.70) per share loss in the same quarter last year.
November 13, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cocrystal Pharma reported a Q3 EPS loss of $(0.41), which is better than the estimated $(0.53) and shows significant improvement from the previous year's $(0.70) loss per share.
Cocrystal Pharma's better-than-expected earnings report is likely to be viewed positively by investors, as it indicates a significant reduction in losses compared to the same period last year. This could lead to increased investor confidence and a potential short-term uptick in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100